Share on StockTwits

Investment analysts at William Blair assumed coverage on shares of Avalanche Biotechnologies (NASDAQ:AAVL) in a note issued to investors on Monday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock.

A number of other firms have also recently commented on AAVL. Analysts at Cowen and Company initiated coverage on shares of Avalanche Biotechnologies in a research note on Monday. They set an “outperform” rating and a $45.00 price target on the stock. Separately, analysts at Piper Jaffray initiated coverage on shares of Avalanche Biotechnologies in a research note on Monday. They set an “overweight” rating on the stock. Finally, analysts at Jefferies Group initiated coverage on shares of Avalanche Biotechnologies in a research note on Monday. They set a “buy” rating and a $40.00 price target on the stock.

Shares of Avalanche Biotechnologies (NASDAQ:AAVL) opened at 30.52 on Monday. Avalanche Biotechnologies has a 52-week low of $22.00 and a 52-week high of $32.375. The stock has a 50-day moving average of $26.28 and a 200-day moving average of $26.28. The company’s market cap is $651.9 million.

Avalanche Biotechnologies, Inc (NASDAQ:AAVL) is a biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.